Inrebic (Fedratinib Dihydrochloride) Patent Expiration, LOE Window & CMS Spending
Inrebic (Fedratinib Dihydrochloride) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2031-11-16 (last listed 2039-09-24), 0 AB generics, $47.7M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N212327 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2031-11-16 |
| Last Listed Patent or Exclusivity Date | 2039-09-24 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $47.7M |
| 2024 Medicare Part D Spend | $44.9M |
| 2024 Medicaid Spend | $2.7M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 20.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.